US2954322A - Pharmaceuticals - Google Patents

Pharmaceuticals Download PDF

Info

Publication number
US2954322A
US2954322A US758921A US75892158A US2954322A US 2954322 A US2954322 A US 2954322A US 758921 A US758921 A US 758921A US 75892158 A US75892158 A US 75892158A US 2954322 A US2954322 A US 2954322A
Authority
US
United States
Prior art keywords
tablet
shellac
polyvinylpyrrolidone
coating
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US758921A
Inventor
Heilig Harland Edward
Jehle Felix Anthony
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olin Corp
Original Assignee
Olin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olin Corp filed Critical Olin Corp
Priority to US758921A priority Critical patent/US2954322A/en
Application granted granted Critical
Publication of US2954322A publication Critical patent/US2954322A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Definitions

  • This invention relates to, and has for its object, the provision of an improved pharmaceutical tablet, and the method of preparing same.
  • Compressed tabletstbat contain a pharmacologically active material (therapeutic agent, medicament) which is hygroscopic or water-soluble, or which is decomposed or inactivated by water (hereinafter referred to as a watersensitive medicament) are prepared in such a way that the water-sensitive medicament, which is present in the center of the tablet (the core) is surrounded by a Waterproof film (moisture barrier film) which is applied to the compressed tablet prior to the coating thereof.
  • the purpose of this film is to prevent the penetration (seepage) of moisture into the core where the moisture could decompose or inactivate the water-sensitive medicament contained therein thereby destroying its therapeutic effectiveness.
  • the primary source of this moisture is the water-based coating syrups which are applied as aqueous solutions to the tablet to impart smoothness and esthetic appearance to the tablet.
  • a natural consequence of such a water-proof film is the prolongation of the disintegration time of the tablet in the gastrointestinal tract, which is generally acceptable but not considered to be ideal inasmuch as the disintegration time of the film coating and consequently the core far exceeds the disintegration period and resultant time of release of the medicament which would give maximum beneficial results of the therapeutic agents being administered in the tablet.
  • oils e.g. peanut oil
  • alcoholic solutions of gums and resins e.g. sandarac
  • higher fatty acids e.g. myristic acid
  • other film formers such as ethyl cellulose.
  • an alcoholic solution of a pharmaceutical grade shellac was used as the Water-proofing agent, the shellac being applied in successive coats.
  • the film formed by the shellac being hard, strong, and insoluble in both water and the dilute acids of the stomach tended to prevent the distintegration of the film in the stomach thereby delaying the release of the therapeutic materials for several hours or until the tablet reached the more alkaline portions of the jejunum.
  • a still further object of this invention is to provide a method of preparing a pharmaceutical tablet containing a core which comprises a water-sensitive medicament and a core coating which essentially comprises shellac and polyvinylpyrrolidone.
  • the objects of this invention can be achieved by coating a tablet core containing a water-sensitive medicament with a solution of shellac and polyvinylpyrrolidone in alcohol.
  • the shellac and polyvinylpyrrolidone together represent about 24-44% (w./w.) of the coating solution, the shellac preferably being present in about 14% of the solution and the polyvinylpyrrolidone preferably being present in about 10-30% of the solution,-about 25% being preferred.
  • water-sensitive medicaments are granulated in the usual manner either by themselves or with other therapeutically active ingredients and/or inactive excipients andcompressed into tablet cores in the manner well known in the art.
  • suitable water-sensitive medicaments may be mentioned hygroscopic materials (e.g. potassium chloride and potassium iodide) antibiotics (e.g. penicillin, nystatin, and tetracycline), vitamins (e.g. ascorbic acid), various iron salts, effervescent salts, salicylate preparations (e.g. acetylsalicyclic acid) and numerous other active medicinal ingredients.
  • the core, thus formed is treated with a solution of shellac and polyvinylpyrrolidone (formed by dissolving the shellac in Warm alcohol and adding the polyvinylpyrrolidone), the shellac and polyvinylpyrrolidone preferably being present in the proportions indicated hereinbefore.
  • This treatment is effected by applying the shellacpolyvinylpyrrolidone solution in successive applications to the tablet core utilizing the conventional methods of coating tablets.
  • the final tablet is then prepared by further coating with a water based coating syrup and if desired, color coatings can be applied until a tablet of desired size and color is obtained.
  • the shellac is dissolved in the alcohol which has been previously warmed to 50 C.
  • the polyvinylpyrrolidone is added, with stirring, until it too has been completely dissolved.
  • the above ingredients are placed in a mixing bowl and thoroughly mixed for 10 or 15 minutes.
  • the mixture is then placed in a tablet machine and compressed.
  • the compressed tablets are removed from the tablet machine, placed in a container and broken into coarse pieces.
  • the broken tablet pieces are then screened to obtain uniform particles and placed in the tablet machine and again compressed.
  • Example II The procedure of Example I is repeated with the following coating composition substituted for that in step a of Example I:
  • Polyvinylpyrrolidone K30 (Antara Chemicals) 7 1 gm 30 Shellac, Orange Flake (pharmaceutical grade, ar-
  • Example III The procedure of Example I is repeated with the following coating composition substituted for that in step a of Example I:
  • Polyvinylpyrrolidone K30 (Antara Chemicals) gm. 25 Shellac, Orange Flake (pharmaceutical grade, a
  • a tablet intended for oral administration comprising a core containing a water-sensitive medicament and a coating thereof which essentially comprises shellac and polyvinylpyrrolidone in the proportion of about one part by weight of shellac to from about 0.7 to about 2.2 parts by weight of polyvinylpyrrolidone.
  • a multi-coated tablet intended for oral use comprising a core containing a Water-sensitive medicament, a film, of shellac and polyvinylpyrrolidone surrounding said core, and a coating of a water soluble material surrounding said film, said film comprising about one part by weight of shellac to from about 0.7 to about 2.2 parts by Weight of polyvinylpyrrolidone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Description

United States Patent PHARMACEUTICALS Harland Edward Heilig, Highland Park, N.J., and Felix Anthony Jehle, Brooklyn, N.Y., assignors to Olin Mathieson Chemical Corporation, New York, N.Y., a corporation of Virginia No Drawing. Filed Sept. 4, 1958, Ser. No. 758,921
2 Claims. (Cl. 167-82) This invention relates to, and has for its object, the provision of an improved pharmaceutical tablet, and the method of preparing same.
Compressed tabletstbat contain a pharmacologically active material (therapeutic agent, medicament) which is hygroscopic or water-soluble, or which is decomposed or inactivated by water (hereinafter referred to as a watersensitive medicament) are prepared in such a way that the water-sensitive medicament, which is present in the center of the tablet (the core) is surrounded by a Waterproof film (moisture barrier film) which is applied to the compressed tablet prior to the coating thereof. The purpose of this film is to prevent the penetration (seepage) of moisture into the core where the moisture could decompose or inactivate the water-sensitive medicament contained therein thereby destroying its therapeutic effectiveness. The primary source of this moisture is the water-based coating syrups which are applied as aqueous solutions to the tablet to impart smoothness and esthetic appearance to the tablet. A natural consequence of such a water-proof film is the prolongation of the disintegration time of the tablet in the gastrointestinal tract, which is generally acceptable but not considered to be ideal inasmuch as the disintegration time of the film coating and consequently the core far exceeds the disintegration period and resultant time of release of the medicament which would give maximum beneficial results of the therapeutic agents being administered in the tablet.
Among the substances previously utilized to provide a water-proof (moisture barrier) film to the compressed tablet prior to coating were oils (e.g. peanut oil), alcoholic solutions of gums and resins (e.g. sandarac), higher fatty acids (e.g. myristic acid) and other film formers such as ethyl cellulose. Most commonly, an alcoholic solution of a pharmaceutical grade shellac was used as the Water-proofing agent, the shellac being applied in successive coats. The film formed by the shellac being hard, strong, and insoluble in both water and the dilute acids of the stomach tended to prevent the distintegration of the film in the stomach thereby delaying the release of the therapeutic materials for several hours or until the tablet reached the more alkaline portions of the jejunum.
It, therefore, is an object of this invention to provide a pharmaceutically acceptable liquid composition intended for use as a tablet core coating composition that is sufficiently impervious to water to act as a moisture barrier film but which disintegrates at an adequate rate in the stomach to permit release of the medicament therein.
It is a further object of this invention to provide tablets intended for oral administration containing a core which comprises a water-sensitive medicament and a coating thereof which essentially comprises shellac and polyvinylpyrrolidone.
A still further object of this invention is to provide a method of preparing a pharmaceutical tablet containing a core which comprises a water-sensitive medicament and a core coating which essentially comprises shellac and polyvinylpyrrolidone.
The objects of this invention can be achieved by coating a tablet core containing a water-sensitive medicament with a solution of shellac and polyvinylpyrrolidone in alcohol. The shellac and polyvinylpyrrolidone together represent about 24-44% (w./w.) of the coating solution, the shellac preferably being present in about 14% of the solution and the polyvinylpyrrolidone preferably being present in about 10-30% of the solution,-about 25% being preferred.
To prepare the tablets of this invention one or more water-sensitive medicaments are granulated in the usual manner either by themselves or with other therapeutically active ingredients and/or inactive excipients andcompressed into tablet cores in the manner well known in the art. Among suitable water-sensitive medicaments may be mentioned hygroscopic materials (e.g. potassium chloride and potassium iodide) antibiotics (e.g. penicillin, nystatin, and tetracycline), vitamins (e.g. ascorbic acid), various iron salts, effervescent salts, salicylate preparations (e.g. acetylsalicyclic acid) and numerous other active medicinal ingredients.
The core, thus formed is treated with a solution of shellac and polyvinylpyrrolidone (formed by dissolving the shellac in Warm alcohol and adding the polyvinylpyrrolidone), the shellac and polyvinylpyrrolidone preferably being present in the proportions indicated hereinbefore. This treatment is effected by applying the shellacpolyvinylpyrrolidone solution in successive applications to the tablet core utilizing the conventional methods of coating tablets.
The final tablet is then prepared by further coating with a water based coating syrup and if desired, color coatings can be applied until a tablet of desired size and color is obtained.
The following examples are illustrative, but by no means limitative, of the invention:
EXAMPLE I (a) Preparation of the coating composition Polyvinylpyrrolidone K30 (Antara Chemicals) gm 10 Shellac, Orange Flake (pharmaceutical grade,
arsenic free) em 14 Ethyl Alcohol SD-3A, q.s. ml
The shellac is dissolved in the alcohol which has been previously warmed to 50 C. When the shellac has been completely dissolved, the polyvinylpyrrolidone is added, with stirring, until it too has been completely dissolved.
(b) Preparation of the tablet core Grams Acetylsalicyclic acid r 975.0 Corn starch 85.0
Acacia 27.5
Talc 27.5
The above ingredients are placed in a mixing bowl and thoroughly mixed for 10 or 15 minutes. The mixture is then placed in a tablet machine and compressed. The compressed tablets are removed from the tablet machine, placed in a container and broken into coarse pieces. The broken tablet pieces are then screened to obtain uniform particles and placed in the tablet machine and again compressed.
(c) Coating the tablet core (d) Coating the tablet The dried and sifted shellac-polyvinylpyrrolidone coated tablets are returned to a coating pan and the pan is rotated. To the tumbling tablets, in the rotating coating pan, are added successive coats of an aqueous solufinishing coats of chocolate syrupare added and the tablets dried and polished to a high luster.
EXAMPLE II The procedure of Example I is repeated with the following coating composition substituted for that in step a of Example I:
Polyvinylpyrrolidone K30 (Antara Chemicals) 7 1 gm 30 Shellac, Orange Flake (pharmaceutical grade, ar-
senic free) gm 14 Ethyl Alcohol SD3A, q.s ml 100 EXAMPLE III The procedure of Example I is repeated with the following coating composition substituted for that in step a of Example I:
Polyvinylpyrrolidone K30 (Antara Chemicals) gm. 25 Shellac, Orange Flake (pharmaceutical grade, a
senic free) gm 14 Ethyl Alcohol SD-3A, q.s ml 100 The invention may be variously otherwise embodied within the scope of the appended claims.
What is claimed is:
1. A tablet intended for oral administration comprising a core containing a water-sensitive medicament and a coating thereof which essentially comprises shellac and polyvinylpyrrolidone in the proportion of about one part by weight of shellac to from about 0.7 to about 2.2 parts by weight of polyvinylpyrrolidone.
2. A multi-coated tablet intended for oral use comprising a core containing a Water-sensitive medicament, a film, of shellac and polyvinylpyrrolidone surrounding said core, and a coating of a water soluble material surrounding said film, said film comprising about one part by weight of shellac to from about 0.7 to about 2.2 parts by Weight of polyvinylpyrrolidone.
References Cited in the file of this patent UNITED STATES PATENTS 2,691,619 Bavley Oct. 12, 1954 2,820,741 Endicott Jan. 21, 1958 FOREIGN PATENTS 109,438 Australia Jan. 11, 1940 493,934 Great Britain Jan. 14, 1937 OTHER REFERENCES,
Schimmel Briegs, No. 233, August 1954.
Proceeding 40th Mid-year Meeting of Chem. Specialties Manuf. Assn, May 1954-, art. by Wilkinson et al., pp. 25-29.

Claims (1)

1. A TABLET INTENDED FOR ORAL ADMINISTRATION COMPRISING A CORE CONTAINING A WATER-SENSITIVE MEDICAMENT AND A COATING THEREOF WHICH ESSENTIALLY COMPRISES SHELLAC AND POLYVINYLPYRROLIDONE IN THE PROPORTION OF ABOUT ONE PART BY WEIGHT OF SHELLAC TO FROM ABOUT 0.7 TO ABOUT 2.2 PARTS BY WEIGHT OF POLYVINYLPYRROLIDONE.
US758921A 1958-09-04 1958-09-04 Pharmaceuticals Expired - Lifetime US2954322A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US758921A US2954322A (en) 1958-09-04 1958-09-04 Pharmaceuticals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US758921A US2954322A (en) 1958-09-04 1958-09-04 Pharmaceuticals

Publications (1)

Publication Number Publication Date
US2954322A true US2954322A (en) 1960-09-27

Family

ID=25053653

Family Applications (1)

Application Number Title Priority Date Filing Date
US758921A Expired - Lifetime US2954322A (en) 1958-09-04 1958-09-04 Pharmaceuticals

Country Status (1)

Country Link
US (1) US2954322A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097144A (en) * 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US3116206A (en) * 1961-12-22 1963-12-31 Ncr Co Encapsulation process and its product
US3256153A (en) * 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US3390049A (en) * 1964-12-23 1968-06-25 Smith Kline French Lab Pharmaceutical tablets coated with wax-free ammonia solubilized water soluble shellac
US3420931A (en) * 1964-04-23 1969-01-07 Merck Ag E Pharmaceutical dragee
US3485914A (en) * 1966-07-05 1969-12-23 Chem & Pharm Patent Hold Ltd Process for the production of a pharmaceutical antibiotic preparation having delayed therapeutic action and the composition prepared according to such process
US3499959A (en) * 1966-07-05 1970-03-10 Chem & Pharm Patent Hold Ltd Therapeutic tetracycline preparation having delayed therapeutic action and processes for the production of said preparation
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US5494681A (en) * 1992-11-30 1996-02-27 Kv Pharmaceutical Company Tastemasked pharmaceutical materials

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB493934A (en) * 1936-01-17 1938-10-17 Hugo Remmler Ag Dr Improvements in and relating to methods of treating medicaments
US2691619A (en) * 1951-09-18 1954-10-12 Pfizer & Co C Fat-soluble vitamin-containing products and process therefor
US2820741A (en) * 1954-04-29 1958-01-21 Abbott Lab Aluminum aspirin granulation and method for making

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB493934A (en) * 1936-01-17 1938-10-17 Hugo Remmler Ag Dr Improvements in and relating to methods of treating medicaments
US2691619A (en) * 1951-09-18 1954-10-12 Pfizer & Co C Fat-soluble vitamin-containing products and process therefor
US2820741A (en) * 1954-04-29 1958-01-21 Abbott Lab Aluminum aspirin granulation and method for making

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097144A (en) * 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US3116206A (en) * 1961-12-22 1963-12-31 Ncr Co Encapsulation process and its product
US3256153A (en) * 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US3420931A (en) * 1964-04-23 1969-01-07 Merck Ag E Pharmaceutical dragee
US3390049A (en) * 1964-12-23 1968-06-25 Smith Kline French Lab Pharmaceutical tablets coated with wax-free ammonia solubilized water soluble shellac
US3485914A (en) * 1966-07-05 1969-12-23 Chem & Pharm Patent Hold Ltd Process for the production of a pharmaceutical antibiotic preparation having delayed therapeutic action and the composition prepared according to such process
US3499959A (en) * 1966-07-05 1970-03-10 Chem & Pharm Patent Hold Ltd Therapeutic tetracycline preparation having delayed therapeutic action and processes for the production of said preparation
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US5494681A (en) * 1992-11-30 1996-02-27 Kv Pharmaceutical Company Tastemasked pharmaceutical materials

Similar Documents

Publication Publication Date Title
US3148124A (en) Method of preparing sustained release pharmaceutical tablets
KR880001753B1 (en) Process for the preparation of delayed-release form of bromhexine
US2928770A (en) Sustained action pill
US4415547A (en) Sustained-release pharmaceutical tablet and process for preparation thereof
US3538214A (en) Controlled release medicinal tablets
FI56623C (en) SAETT ATT FRAMSTAELLA ORALT INTAGBARA MEDICINFORMER MED FOERLAENGD VERKAN
KR20030034171A (en) Oxymorphone controlled release formulations
JPS6116368B2 (en)
NZ201008A (en) Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
JPH0530804B2 (en)
JPS6345216A (en) Long life prescription
NZ205894A (en) Pharmaceutical compositions containing mopidamol(2,6-bis(diethanolamino)-4-piperidino-pyrimido(5,4-d)pyrimidine)
JPH02270820A (en) Slowly releasable ethodrug
DD201643A5 (en) METHOD FOR PRODUCING AN ACETYL SALICYANIC ACID CONTAINING CAPSULE
KR100202154B1 (en) Film coated tablet of paracetamol and domperidone
IE48879B1 (en) An analgesic effervescent powder and process for its preparation
US2954322A (en) Pharmaceuticals
EP0052076A1 (en) Fast disaggregating pharmaceutical tablet
US4049803A (en) Augmentation of blood levels of aspirin
AU7875794A (en) Controlled release potassium dosage form
US4851233A (en) Sustained release formulations
JPH02288821A (en) Particle and medicine preparation coated with film containing agonist
CA2339942C (en) Extended release acetaminophen
EP0013131A2 (en) Pharmaceutical composition in solid dosage form, and process for its production
US4601895A (en) Delayed-action acetylsalicylic acid formulations for oral administration